Financial, Forecast, Opportunity, Biosimilar, Medicine, Global, Healthcare, Marketplace

Financial Forecast: Opportunities For Biosimilar Medicines In The Global Healthcare Marketplace

At the Biosimilar Drug Development World Europe event 2014, Ashwin Pai, Jefferies International, gave a presentation on “Financial Forecast: Opportunities For Biosimilar Medicines In The Global Healthcare Marketplace.” Download and learn: Biosimilars – Where Do We Stand Today? What Does The Future Hold? Emerging Markets – Opportunity Large Than Previously Expected Developed Markets – Wide Differences Across Markets And Molecules What …

GaBi Journal partners with Total Biopharma, in association with the World Biosimilar Congress, Nov 2014

Guest Post: GaBI – Building trust in cost-effective treatments

A frequent partner of our Life Science conferences, GaBI Journal is an independent and peer reviewed academic journal, encompassing all aspects of generic and biosimilar medicines development and use, from fundamental research up to clinical application and policies. View the latest issue of GaBI Journal to learn about pharmaceutical innovation and developments in generic and biosimilar medicines. Volume 3, 2014, Issue …

Total Biopharma interviews Richard Marlus, Amgen's Executive Medical Director

Amgen’s Executive Medical Director, Richard Markus, talks Biosimilars

In the world of biosimilars, there is quite some activity occurring, from a significant number of products under development to regulatory approvals to watch out for. With this in mind, and in preparation for the World Biosimilar Congress 2014, we’ve taken some time to conduct interviews with key members of the speaker faculty who are influential professionals of the biosimilar …

The future of pharma innovation: Genomic medicine

The future of drug development is undoubtedly tied to personalizing medicine. Understanding a person’s genetic makeup in order to not only detect but treat diseases is at the forefront of medicine nowadays. The Mexican pharma industry has joined this trend as several companies are joining efforts with research institutions to look at the diversity of genetic profiles in the Mexican …

Global Biosimilar/Follow-on Biologic market expected to reach $36bn by 2020

We’re now mid-way through the long anticipated decade of spectacular ‘patent cliffs’. With some of the pharmaceutical industry’s biggest blockbuster biologics coming off patent, it seems that the market for biosimilar and follow-on biologic products is due to explode. A recently released report suggests that the global market will reach $36 billion by the year 2020, up from the estimated …

Review Article: Interchangeability of Biosimilars

NDA Advisory Board member, Paul Chamberlain,  in collaboration with Dr Hans Ebbers (University of Utrecht, The Netherlands) has recently published an article in Generics and Biosimilars Initiative Journal (GaBI Journal) – title “Interchangeability. An insurmountable fifth hurdle?” This article questions whether designation of biosimilar products as “interchangeable” is a feasible objective in the sense where this would allow automatic substitution at …

Review Article: Evaluating Immunogenicity of Biosimilars

Interested in immunogenicity issues in biosimilar medicines?  NDA Advisory Board member, Paul Chamberlain, has recently had an article published in Biosimilars magazine – titled ‘Multidisciplinary approach to evaluating immunogenicity of biosimilars: lessons learnt and open questions based on 10 years’ experience of the European Union regulatory pathway’. The article comprehensively reviews the weight of evidence for EU approval of biosimilar …

Download: Both an innovator and a biosimilar player – an innovator perspective on developing a global biosimilar strategy

Download this presentation here > The World Biosimilar Congress  brings together pharma, biotech, academia and regulators and the wider service provider community to discuss the latest R&D, process, production, regulation and to-market strategies for biosimilar medicines. At the 2013 event, delegates were fortunate enough to hear from Dr Mourad Farouk, Medical Director – International Development, Amgen, who delivered the presentation ‘Both an innovator and a biosimilar player – an …